Actively Recruiting
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-04
28
Participants Needed
7
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.
CONDITIONS
Official Title
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed endometrial carcinoma with eligible histologic subtypes (endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, carcinosarcoma)
- Surgery including hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node assessment
- FIGO (2009) stage IIIA or IIIC1 disease based on surgical staging
- Consent to testing with MSK-IMPACT part A, encouraged to consent to parts A and C
- Age 18 years or older
- Karnofsky Performance Status of 70 or higher (or ECOG 0 or 1)
- Neuropathy grade 1 or less
- No visible residual disease after surgery
- No prior radiation or chemotherapy for endometrial cancer
- No active infection requiring antibiotics except uncomplicated urinary tract infection
- Adequate organ function per specified laboratory criteria within 14 days before treatment
- Enrollment within 12 weeks from surgery date
- Prior or concurrent malignancy allowed if it does not interfere with study assessments
- Childbearing age patients must have had hysterectomy and bilateral oophorectomy
- Agreement not to breastfeed during study and for 150 days after last treatment dose
You will not qualify if you...
- Endometrial cancers with known pathogenic POLE mutations
- Mismatch repair deficient endometrial cancers as determined by specific staining or MSI-H
- Active inflammatory bowel disease such as Crohn's disease or ulcerative colitis
- Conditions or therapies that could affect study results or participation, including uncontrolled arrhythmia, recent heart attack, COPD, uncontrolled seizures, unstable spinal cord compression, superior vena cava syndrome
- Unfit for pelvic radiation therapy including recent radiation involving more than 20% of bone marrow, prior pelvic radiation, or fistula diagnosis
- Hematological abnormalities contraindicating radiation therapy per physician judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (All protocol activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (All protocol activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Commack (All protocol activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (All protocol activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (All protocol activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
K
Kaled Alektiar, MD
CONTACT
V
Vicky Makker, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here